Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and Delirium
Sponsor: Alexandria University
Summary
This study aims to evaluate the clinical efficacy and safety of rivastigmine in reversing the full spectrum of anticholinergic delirium including hypoactive delirium which is presented with CNS depression and hyperactive or agitated delirium. The study was conducted on 100 patients at the Poison Control Center of Alexandria University Main Hospital. The primary objective is to assess the effectiveness of rivastigmine in restoring consciousness and improving cognitive function in patients presenting with delirium and depressed mental status using GCS and RASS score.
Official title: Efficacy of Rivastigmine in the Management of Toxic Anticholinergic Delirium: A Prospective Study at Alexandria Poison Center
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-12-08
Completion Date
2026-04-15
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
Rivastigmine
Initial Dose: A starting dose of 6 mg is administered either orally or via a Nasogastric Tube (NGT) for patients with impaired swallowing or depressed consciousness. Titration: Additional 6 mg doses are repeated every 2 hours based on clinical need until the resolution of delirium. Alternative Route: Transdermal patches (9.5 mg/24h) are applied in cases where enteral administration is not feasible or based on clinical judgment.
Locations (1)
Poison Control Center (PCC), Alexandria University Main Hospital
Alexandria, Egypt